DynaPro Plate Reader Optimizes Screening Process for Biotherapeutic Candidates and Formulations
Wyatt Technology Corporation highlights a study recently authored by Martin Skov Neergaard from the Faculty of Health and Medical Sciences at the University of Copenhagen, “Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration.” This article outlines the benefits of quantifying protein-protein interactions (PPI) using automated dynamic light scattering (DLS) in high-throughput screening (HTS) mode to identify promising candidates for drug-like properties and establish the suitability of formulations before entering extended stability studies. The study, which used Wyatt Technology’s DynaPro Plate Reader II high-throughput DLS instrument, was published by GIT Laboratory and may be downloaded at www.wyatt.com/AppNotes/DLS.
Therapeutic monoclonal antibodies (mAbs) are effective at treating chronic diseases such as autoimmune disorders and cancer. Long-term stability is an important attribute of any commercial drug molecule, and of great interest in biotherapeutics in particular. Measurements of PPI indicate colloidal stability, correlate closely to stability and viscosity at high protein concentration, and are widely used as stability-indicating parameters (SIPs) in pre-selecting monoclonal antibody biotherapeutic molecules and formulation conditions before launching the arduous process of long-term stability testing. Ordinarily, PPI studies require significant quantities of sample and labor. Optimal screening processes of PPI will allow drug developers to identify and concentrate development on the most promising mAbs and formulations, saving considerable time and money while decreasing time-to-market.
The study showcases some novel uses of DLS to rapidly provide substantial information about the stability and viscosity of a formulation. Traditionally, PPI are quantified by static light scattering (SLS) as the second virial co-efficient (B22), though recently other techniques have come into widespread use. DLS has proven extremely useful in this field as it provides substantially more information regarding SIPs, with less sample, than standard SLS. DLS quantifies PPI via the diffusion interaction parameter (kD), and Neergaard also explored the relative radius method comparing apparent hydrodynamic radii at low and high concentrations. These methods, using kD and relative radius to quantify PPI in a protein solution, make the process of characterization much quicker and simpler than standard methods.
The DynaPro Plate Reader II is capable of running high-throughput, automated HTS-DLS analyses to characterize PPI in standard microwell plates, under multiple conditions in a significantly reduced time frame, making DLS a viable option for SIP screening. As an added benefit, DLS measures the viscosity of highly concentrated proteins with the same high throughput and low sample consumption. The onset points of aggregation or melting may be obtained in the DynaPro via temperature ramps or chemical denaturing, to assess additional SIPs for conformational stability, making the DynaPro DLS plate reader the ultimate tool for developability and formulation screening.
“Techniques for determining protein stability are still widely debated amongst researchers, and a combination of stability-indicating parameters must be weighed to get a complete picture,” explains Dr Daniel Some, Director of Marketing and Principal Scientist at Wyatt Technology, “Optimization of screening processes to reduce time and resources spent on ensuring long-term viability is a key consideration in the drug development process. The DynaPro Plate Reader II ensures comprehensive testing, over a range of conditions in minimal time, and eliminates the need for additional laboratory apparatus when screening the stability-indicating parameters of high concentration protein formulations.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance